DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. METHODS: This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. RESULTS: We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48-73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14-24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR, 1.02 and 1.56, respectively; P < .03), with significant interaction with sickness severity status. CONCLUSIONS: Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association (167,(171)(172)(173).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [171]
In the citing paper
“Antibiotics are subject to changes in PK/PD parameters in sepsis and septic shock where resultant concentrations may be too low risking clinical failure, or too high leading to toxicity (Table 3) [237–239].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [238]
Citations
Cites
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376 · cited 1×
“Various demographic and clinical data were collected including age, sex, height, weight, presence of renal replacement therapy, and measures of organ function and levels of patient sickness severity as described by the APACHE II (Acute Physiology and Chronic Health Evaluation II) score [15] on admission and SOFA (Sequ…”
MethodKumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundHarbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464 · cited 2×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundResultSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414 · cited 1×
“These patients may have augmented renal clearances needing either higher doses or more frequent dosing to overcome increased drug elimination [22, 23].”
BackgroundSelf-citationAntibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408 · cited 2×
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
Background
Cited by
Items 501–600 of 1,000
Nicolau, D. P., Dimοpoulos, G., Welte, T., & Luyt, C. E. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1190277 · Cited by 13
“bronchopulmonary to epithelial lining fluid [ELF]), and increased resistance with loss of antimicrobial potency [43,44].”
BackgroundSulaiman, H., Abdul-Aziz, M. H., & Roberts, J. A. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1602716 · Cited by 13
Self-citationBarton, G. J., Morecroft, C. W., & Henney, N. C. (2019) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-019-00938-9 · Cited by 13
Target-Controlled Infusion of Cefepime in Critically Ill Patients
Jonckheere, S., Neve, N. D., Verbeke, J., Decker, K. D., Brandt, I., Boel, A., Bocxlaer, J. V., Struys, M. M. R. F., & Colin, P. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01552-19 · Cited by 13
Are β-lactam concentrations adequate in severe sepsis and septic shock in children?
Chosidow, A., Benaboud, S., Béranger, A., Zheng, Y., Moulin, F., Dupic, L., Renolleau, S., Tréluyer, J., & Oualha, M. (2020) · Therapies · doi:10.1016/j.therap.2020.04.007 · Cited by 14
Brasier, N., Osthoff, M. F., Ieso, F. D., & Eckstein, J. (2021) · Journal of Medical Internet Research · doi:10.2196/25907 · Cited by 15
“Appropriate dosing is crucial, as previous evidence indicates significant interpersonal variability in antibiotic serum concentration and a low chance of achieving even the most conservative pharmacological target [62].”
Lee, J. H., Lee, D. H., Kim, J. S., Jung, W., Heo, W., Kim, Y. K., Kim, S. H., No, T.-H., Jo, K. M., Ko, J., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.768912 · Cited by 13
“We implemented Monte Carlo simulations to evaluate the PTA when the treatment targets were, 100% fT>MIC and 100% fT>4xMIC as well as 40% fT>MIC for meropenem, because the more aggressive targets of 100% fT>MIC or 100% fT>4xMIC has been suggested to improve clinical outcome for critically ill patients in intensive care…”
MethodTherapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory
Shipkova, M., & Jamoussi, H. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000934 · Cited by 13
Richter, D., Heininger, A., Chiriac, U., Frey, O. R., Rau, H., Fuchs, T., Röhr, A. C., Brinkmann, A., & Weigand, M. A. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000949 · Cited by 13
Razzazzadeh, S., Darazam, I. A., Hajiesmaeili, M., Salamzadeh, J., Mahboubi, A., Sadeghnezhad, E., & Sahraei, Z. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03291-5 · Cited by 13
Whited, L. K., Grove, M. E., Rose, D. T. T., Rhodes, N. J., Scheetz, M. H., O’Donnell, J. N., Neeb, J. L., Thoele, K., Jones, D. R., Lowe, C., et al. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1807 · Cited by 13
“Likewise, a multinational PK point-prevalence study that included eight b-lactam antibiotics found that achieving fT>MIC of 100% in a general population improved the odds of a positive clinical outcome.(18) In addition, another group found that achieving fT>MIC of 100% was possible with concentration monitoring and do…”
BackgroundCies, J. J., LaCoursiere, R. J., Moore, W. S., & Chopra, A. (2017) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-22.6.467 · Cited by 14
Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment
Gorham, J., Taccone, F. S., & Hites, M. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2056012 · Cited by 14
“critically ill patients, the inability to attain a T > MIC > 50% was associated with a 32% decreased likelihood of a positive clinical outcome [17].”
BackgroundSelf-citationWinstead, E. M., Ratliff, P. D., Hickson, R. P., Mueller, J. E., & Judd, W. R. (2016) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-016-0334-1 · Cited by 13
Craig, W. A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu055 · Cited by 13
“of Clinical Infectious Diseases [3] has defined antibiotic levels in intensive care unit patients (the DALI study) by measuring plasma or serum levels at 50% and”
InfluentialKoch, B. C. P., Muller, A. E., Hunfeld, N., de Winter, B. C. M., Ewoldt, T. M. J., Abdulla, A., & Endeman, H. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000942 · Cited by 21
Individual meropenem epithelial lining fluid and plasma PK/PD target attainment
Rohani, R., Yarnold, P. R., Scheetz, M. H., Neely, M. N., Kang, M., Donnelly, H. K., Dedicatoria, K., Nozick, S. H., Medernach, R. L., Hauser, A. R., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00727-23 · Cited by 14
“A minimally acceptable lower bound for T >MIC appears to be 50% based on prior research (21).”
BackgroundMethodRueda, F. R., Méndez, R., Suárez-de-la-Rica, A., González, R., & Maseda, E. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010106 · Cited by 17
Laporte-Amargós, J., Carmona-Torre, F., Huguet, M., Puerta‐Alcalde, P., Rigo-Bonnin, R. F., Ulldemolins, M., Arnán, M., del Pozo, J. L., Torrent, A., García‐Vidal, C., et al. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.10.006 · Cited by 12
O’Jeanson, A., Nielsen, E. I., & Friberg, L. E. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae375 · Cited by 12
Barreto, E. F., Rule, A. D., Al‐Shaer, M. H., Roberts, J. A., Abdul-Aziz, M. H., Scheetz, M. H., Mara, K. C., Jannetto, P. J., Gajic, O., O’Horo, J. C., et al. (2021) · Implementation Science Communications · doi:10.1186/s43058-021-00134-9 · Cited by 12
“Substantial inter- [7, 8] and intra-patient [9] variability in betalactam concentrations have been observed in critically ill patients which is thought to contribute to suboptimal effectiveness, safety, and development of antibiotic resistance [10].”
BackgroundSelf-citationThe effect of delays in second-dose antibiotics on patients with severe sepsis and septic shock
Lykins, J. D., V, Kuttab, H. I., Rourke, E. M., Hughes, M. D., Keast, E. P., Kopec, J. A., Ward, B., Pettit, N. N., & Ward, M. A. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.03.057 · Cited by 16
Jung, Y. J., Kim, E. J., & Choi, Y. H. (2021) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.277 · Cited by 12
“277 compromises optimal drug penetration [10].”
Kidd, J. M., Asempa, T. E., & Abdelraouf, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00013-1 · Cited by 14
Jarrett, P., Keogh, S. J., Roberts, J. A., Wallis, S. C., & Coyer, F. M. (2023) · Intensive and Critical Care Nursing · doi:10.1016/j.iccn.2023.103403 · Cited by 12
Self-citationPrinz, C., Streit, F., Schumann, C., Dudakova, A., Lanckohr, C., Schanz, J., Bohn, M., Groß, U., Meissner, K., Moerer, O., et al. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01257-8 · Cited by 12
Schmid, S. A., Koch, C., Zimmermann, K., Buttenschoen, J., Mehrl, A., Pavel, V., Schlosser‐Hupf, S., Fleischmann, D., Krohn, A., Schilling, T., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12121730 · Cited by 13
Paice, K. M., Girdwood, S. T., Mizuno, T., Pavia, K. E., Punt, N. C., Tang, P., Dong, M., Curry, C., Jones, R., Gibson, A., et al. (2024) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000003599 · Cited by 12
Antimicrobial stewardship of β-lactams in intensive care units
Cotta, M. O., Roberts, J. A., Tabah, A., Lipman, J., Vogelaers, D., & Blot, S. I. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.902308 · Cited by 16
Self-citationPersonalised beta-lactam therapy: basic principles and practical approach
Streit, F., Perl, T., Schulze, M. H., & Binder, L. (2016) · Journal of Laboratory Medicine · doi:10.1515/labmed-2016-0050 · Cited by 12
Ramos, J. R., Favieres, C., Porcar, M. J. B., Villarreal, E., Gordón, M., Quinzá, A., Castellanos-Ortega, Á., & Ramírez, P. (2017) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2016-001114 · Cited by 12
Development and validation of a dosing nomogram for amoxicillin in infective endocarditis
Rambaud, A., Gaborit, B. J., Deschanvres, C., Turnier, P. L., Lecomte, R., Asseray-Madani, N., Leroy, A., Deslandes, G., Dailly, É., Jolliet, P., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa232 · Cited by 13
The case for precision dosing: medical conservatism does not justify inaction
Scheetz, M. H., Lodise, T. P., Downes, K. J., Drusano, G. L., & Neely, M. N. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab086 · Cited by 15
Augmented renal clearance. An unnoticed relevant event
Tomasa-Irriguible, T. M., Sabater‐Riera, J., Pérez-Carrasco, M., Ballujera, P. O., Buendía, Y. D., Navas, A., Betbese, A. J., Rodríguez-López, M., Ibarz-Vilamayor, M., Olmo-Isasmendi, A., et al. (2021) · Science Progress · doi:10.1177/00368504211018580 · Cited by 12
“A clear association exists between ARC and infra therapeutic plasma levels of betalactams.(1) ARC is defined as a creatinine clearance greater than 130ml/min/ 1.”
BackgroundKıran, P., Nadir, Y., & Gençer, S. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.05.008 · Cited by 12
Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects
Poulakou, G., Matthaiou, D. K., Nicolau, D. P., Siakallis, G., & Dimοpoulos, G. (2017) · Drugs · doi:10.1007/s40265-017-0787-0 · Cited by 13
“Furthermore, in MV patients, altered antibiotic pharmacokinetics has been recently recognized as an important factor compromising optimal drug penetration [21, 22].”
Optimal antibiotic use in the intensive care unit
Micek, S. T., Vazquez Guillamet, M. C., Reynolds, D., Matuszak, S., Kolodziej, L., & Kollef, M. H. (2025) · Critical Care · doi:10.1186/s13054-025-05653-8 · Cited by 11
“Not surprisingly, the percentage of antibiotic administrations achieving this target is consistently deemed to be insufficient in the early and subsequent treatment phases of sepsis when beta-lactams are administered via intermittent infusions [55, 56].”
Smekal, A.-K., Furebring, M., Lipcsey, M., & Giske, C. G. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad327 · Cited by 11
“6,7 However, the testing was seldom performed with the reference MIC method, broth microdilution (BMD), and often the actual MIC (MIC ACTUAL ) was used without adjusting for the technical variability of MIC testing.”
BackgroundMethodResultInfluentialMahmoud, A. A., Shah, A., Nutley, K., Nicolau, D. P., Sutherland, C. A., Jain, M., Scheetz, M. H., & Rhodes, N. J. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.03.003 · Cited by 11
Šíma, M., Michaličková, D., Ryšánek, P., Cihlářová, P., Kuchař, M., Lžičařová, D., Beroušek, J., Hartinger, J. M., Vymazal, T., & Slanař, O. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081156 · Cited by 11
Riezk, A., Vasikasin, V., Wilson, R. C., Rawson, T. M., McLeod, J. G., Dhillon, R., Duckers, J. M., Cass, A. E. G., & Holmes, A. H. (2023) · Analytical Methods · doi:10.1039/d2ay01459a · Cited by 11
Pharmacokinetics/pharmacodynamics of ceftobiprole in patients on extracorporeal membrane oxygenation
Coppens, A., Zahr, N., Chommeloux, J., Bleibtreu, A., Hékimian, G., de Chambrun, M. P., Lefèvre, L., Schmidt, M., Robert, J., Junot, H., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106765 · Cited by 11
Öbrink‐Hansen, K., Wiggers, H., Bibby, B. M., Hardlei, T. F., Jensen, K. T., Thomsen, M. K., Brock, B., & Petersen, E. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12661 · Cited by 12
Chan, J. D., Dellit, T. H., & Lynch, J. B. (2017) · Journal of Intensive Care Medicine · doi:10.1177/0885066617708756 · Cited by 11
Declercq, P. E., Gijsen, M., Meijers, B. K. I., Schetz, M. R. C., Nijs, S., D’Hoore, A., Wauters, J., & Spriet, I. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12695 · Cited by 11
Self-citationWitcher, R., Tracy, J., dos Santos, L. S., & Chopra, A. (2019) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-24.6.497 · Cited by 11
Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients
Veillette, J. J., Winans, S. A., Maskiewicz, V. K., Truong, J. Q., Jones, R. N., & Forland, S. C. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00677-1 · Cited by 11
Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia
Alsultan, A., Dasuqi, S. A., Aljamaan, F., Omran, R. A., Syed, S. A., AlJaloud, T., Alahmadi, A. E. A., Alqahtani, S., & Hamad, M. A. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.09.017 · Cited by 12
“In the study by Roberts et al. 59% of patients had subtherapeutic concentrations (Roberts et al., 2014).”
InfluentialIyer, R. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00212-7 · Cited by 21
Matusik, É., Lemtiri, J., Wabont, G., & Lambiotte, F. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02678-x · Cited by 11
Roelofsen, E. E., Abdulla, A., Muller, A. E., Endeman, H., Gommers, D. A. M. P. J., Dijkstra, A., Hunfeld, N., de Winter, B. C. M., & Koch, B. C. P. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15487 · Cited by 11
“compared to healthy volunteers or patients with less severe illnesses or infections.(1,2) Exposure to antibiotics in critically ill patients can be affected by changes in the PK due to altered renal function (dysfunc-”
BackgroundPlasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?
Ewoldt, T. M. J., Bahmany, S., Abdulla, A., Muller, A. E., Endeman, H., & Koch, B. C. P. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad046 · Cited by 11
Evaluation of continuous ampicillin/sulbactam infusion in critically ill patients
Passon, S. G., Schmidt, A. R., Wittmann, M., Velten, M., & Baehner, T. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121567 · Cited by 12
Significant publications on infectious diseases pharmacotherapy in 2014
Phe, K., Cadle, R. M., Guervil, D. J., Guzmán, O. E., Lockwood, A. M., Perez, K. K., Vuong, N. N., & Aitken, S. L. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150112 · Cited by 11
ESTRATEGIAS PARA EL USO DE ANTIBIÓTICOS EN PACIENTES CRÍTICOS
Arancibia, J. M. (2019) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2019.03.001 · Cited by 18
Lowman, W. (2018) · South African Medical Journal · doi:10.7196/samj.2018.v108i9.13285 · Cited by 11
Chai, M. G., Tu, Q., Cotta, M. O., Bauer, M. J., Balch, R., Okafor, C. E., Comans, T. A., Krüger, P., Meyer, J., Shekar, K., et al. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07353-3 · Cited by 10
Self-citationClinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Shah, S., Clarke, L. G., Davis, M. W., Topal, J. E., & Shields, R. K. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae205 · Cited by 10
Baptista, J. P. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_7 · Cited by 10
Self-citationIndividualized antibiotic therapy in the treatment of severe infections
Annoni, F., Grimaldi, D., & Taccone, F. S. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1696192 · Cited by 12
Self-citationThe future of antimicrobial dosing in the ICU: an opportunity for data science
Corte, T. D., Elbers, P., & Waele, J. J. D. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06549-1 · Cited by 10
Alves, J., Abreu, B., Palma, P., Alp, E., Vieceli, T., & Rello, J. (2023) · Microorganisms · doi:10.3390/microorganisms11051127 · Cited by 10
“Continuous prolonged infusion of beta-lactams increases efficacy and is associated with better outcomes [97,100,101].”
BackgroundInfluentialSelf-citationHe, Y., Geng, S., Mei, Q., Zhang, L., Yang, T., Zhu, C., Fan, X., Wang, Y., Tong, F., Gao, Y., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s424802 · Cited by 10
Antibiotic dose optimisation in the critically ill: targets, evidence and future strategies
Dyer, C. J., Waele, J. J. D., & Roberts, J. A. (2024) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001187 · Cited by 12
Self-citationFirst dose target attainment with extended infusion regimens of piperacillin and meropenem
Beijer, G., Swartling, M., Nielsen, E. I., Breuer, O., Giske, C. G., Eliasson, E., & Petersson, J. (2025) · Critical Care · doi:10.1186/s13054-025-05445-0 · Cited by 10
Yavuz, S. Ş., Akar, A., Aydoğdu, S., Berzeg-Deniz, D., Demir, H., Hazırolan, T., Özatık, M. A., Özer, N., Sarğın, M., Topçuoğlu, N., et al. (2020) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2020.01954 · Cited by 13
Gastine, S., Hsia, Y., Clements, M., Barker, C. I. S., Bielicki, J. A., Hartmann, C., Sharland, M., & Standing, J. F. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2180 · Cited by 10
“In critical care the 100%f T > MIC target, however, resulted in favorable outcomes according to the defining antibiotic levels in intensive care unit patients (DALI) trial.(42) The desired PD targets, however, still remain to be elucidated across different routes of administration and patient populations.”
BackgroundMethodAntibiotic Optimization in the Intensive Care Unit
Lizza, B. D., Raush, N., & Micek, S. T. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1740972 · Cited by 12
Chen, C., Seabury, R. W., Steele, J. M., Parsels, K. A., Darko, W., Miller, C. D., & Kufel, W. D. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac117 · Cited by 10
Weinelt, F. A., Stegemann, M. S., Theloe, A., Pfäfflin, F., Achterberg, S., Weber, F., Dübel, L., Mikołajewska, A., Uhrig, A., Kießling, P., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11060758 · Cited by 10
Balaban, N. Q., & Liu, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-25241-0_1 · Cited by 12
Marsot, A. (2020) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30927 · Cited by 10
Pharmacokinetics of multiple doses of teicoplanin in Chinese elderly critical patients
Wang, S., Lin, F., Ruan, J., Ye, H., & Wang, L. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1449107 · Cited by 10
Research Agenda for Antimicrobial Stewardship in the Veterans Health Administration
Suda, K. J., Livorsi, D. J., Goto, M., Forrest, G. N., Jones, M., Neuhauser, M. M., Hoff, B. M., İnce, D., Carrel, M., Nair, R., et al. (2018) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2017.299 · Cited by 10
The role of mass spectrometry in antibiotic stewardship
Zander, J., Paal, M., & Vogeser, M. (2018) · Clinical mass spectrometry · doi:10.1016/j.clinms.2018.11.001 · Cited by 10
Editorial Commentary: Antimicrobial De-escalation: What's in a Name?
Kollef, M. H., & Micek, S. T. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ1201 · Cited by 11
Mei-Sheng Riley, M., & Olans, R. (2021) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2021.07.001 · Cited by 9
Prolonged Beta-Lactam Infusions in Children: A Systematic Review and Meta-Analysis
Briand, A., Bernier, L., Pincivy, A., Roumeliotis, N., Autmizguine, J., Marsot, A., Métras, M., & Thibault, C. (2024) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2024.114220 · Cited by 10
Bradley, J. S., Harvey, H. A., Stout, D., Momper, J. D., Capparelli, E. V., Avedissian, S. N., Barbato, C., MAK, R. H. K., Jones, T. P., Jones, D., et al. (2025) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000003698 · Cited by 9
Qi, Z., Zhang, S., Li, J., Qian, S., Song, D., & Ye, X. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124699 · Cited by 10
Willam, C., Abu-Tair, M., Bayer, M., Bellmann, R., Brunkhorst, F. M., Custodis, F., Galle, J. C., Hermes, C., Joannidis, M., John, S., et al. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01293-6 · Cited by 9
Lalanne, S., Vée, M. L., Lemaitre, F., Corre, P. L., Verdier, M., & Fardel, O. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12541 · Cited by 9
Al‐Shaer, M. H., Mazirka, P., Burch, G. M., Peloquin, C. A., Drabick, Z., & Carson, J. S. (2022) · Journal of Burn Care & Research · doi:10.1093/jbcr/irac099 · Cited by 9
Population pharmacokinetics of amikacin in suspected cases of neonatal sepsis
Severino, N., Urzúa, S., Ibacache, M. E., Paulos, C., Cortínez, L. I., Toso, A., Leguizamón, L., Inojosa, R., Maccioni, A., Meza, S., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15697 · Cited by 9
“This hyperdynamic state characterized by increased heart rate, decreased systemic vascular resistance and increased cardiac output (CO) has shown to influence the pharmacokinetics of drugs with renal excretion, increasing their clearance.(29) In our study, the presence of sepsis was associated with a 31% increase in c…”
BackgroundAn, G., Creech, C. B., Wu, N., Nation, R. L., Gu, K., Nalbant, D., Jimenez‐Truque, N., Fissell, W. H., Patel, P. C., Fishbane, N., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad106 · Cited by 9
Gras-Martín, L., Plaza‐Díaz, A., Tamames, B. Z., Vera, P., Torres, O. H., Bastida, C., Soy, D., & Ramos, J. R. (2024) · Antibiotics · doi:10.3390/antibiotics13090801 · Cited by 10
Kim, Y. K., Kang, G., Zang, D. Y., & Lee, D. H. (2024) · Antibiotics · doi:10.3390/antibiotics13090849 · Cited by 9
Stewart, A. G., Graves, B., Hajkowicz, K. M., Ta, K., & Paterson, D. L. (2015) · Microbial Drug Resistance · doi:10.1089/mdr.2015.0006 · Cited by 9
Parker, S. L., Saxena, M. K., Gowardman, J. R., Lipman, J., Myburgh, J., & Roberts, J. A. (2018) · Journal of Critical Care · doi:10.1016/j.jcrc.2018.05.016 · Cited by 9
“Highly variable volumes of distribution are not unexpected due to changes to volume of extracellular fluid and drug-protein binding characteristics, which are also often experienced in patients in intensive care [21].”
BackgroundSelf-citationSOP Individuelle Dosierung und Applikation von Antiinfektiva auf der Intensivstation
Röhr, A. C., Koeberer, A., Fuchs, T., von Freyberg, P., Frey, O. R., & Brinkmann, A. (2018) · Intensivmedizin up2date · doi:10.1055/a-0626-8184 · Cited by 9
“Intensive Care Med 2016; 42: 1535–1545 [15] Roberts JA, Paul SK, Akova M et al.”
BackgroundTherapeutic drug monitoring of antibiotics in critically ill patients
Horn, D., Klaas, C., Fobker, M., Köck, R., & Lanckohr, C. (2019) · Handbook of analytical separations · doi:10.1016/b978-0-444-64066-6.00008-3 · Cited by 9
Donnellan, S., Wright, D. F. B., Roberts, J. A., Duffull, S. B., Schollum, J. B. W., Putt, T. L., Wallis, S. C., & Walker, R. J. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02792-0 · Cited by 9
Self-citationChiriac, U., Frey, O. R., Roehr, A. C., Koeberer, A., Gronau, P., Fuchs, T., Roberts, J. A., & Brinkmann, A. (2021) · Medicine · doi:10.1097/md.0000000000026253 · Cited by 10
“In contrast to our findings, antibiotic standard dosing without TDM showed a remarkably high PK-target nonattainment.([11]) In the DALI study, only 35% and 60% of the patients achieved 100% fT>4xMIC (ampicillin 22%, piperacillin 30%, cefepime 71%, meropenem 42%) and”
BackgroundResultInfluentialSelf-citationAntibiotic De-Escalation in Emergency General Surgery
Vallicelli, C., Minghetti, M., Sartelli, M., Coccolini, F., Ansaloni, L., Agnoletti, V., Bravi, F., & Catena, F. (2022) · Antibiotics · doi:10.3390/antibiotics11091148 · Cited by 10
“It has been estimated that one out of six patients receiving beta-lactams does not reach the minimal concentration target and many more do not reach the target associated with maximal bacterial killing [24].”
BackgroundBaalbaki, N., Blum, S. S., Akerman, M. B., & Johnson, D. E. (2022) · Journal of Pharmacy Technology · doi:10.1177/87551225221121252 · Cited by 9
Kang, S., Yang, S., Hahn, J., Jang, J. Y., Min, K. L., Wi, J. H., & Chang, M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226621 · Cited by 9
Campbell, P. O., Chin, P. K. L., Dalton, S. C., Metcalf, S. C. L., Douglas, N. M., & Chambers, S. T. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106695 · Cited by 10
Wieringa, A., Ewoldt, T. M. J., Gangapersad, R. N., Gijsen, M., Parolya, N., Kats, C. J. A. R., Spriet, I., Endeman, H., Haringman, J. J., van Hest, R. M., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12121674 · Cited by 9
Huang, Z., Yang, X., Jin, Y. C., Yu, J., Cao, G., Wang, J., Hu, Y., Dai, J., Wu, J., Wei, Q., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01330-23 · Cited by 9
Čižmárová, I., Mikuš, P., Švidrnoch, M., & Piešťanský, J. (2024) · Pharmaceuticals · doi:10.3390/ph17040526 · Cited by 9
Metadata
- Authors
- Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Starr, T., Wallis, S. C., Lipman, J., Study, D., Roberts, J. A., Lipman, J., Starr, T., Wallis, S. C., Paul, S. K., Margarit Ribas, A., De Waele, J. J., De Crop, L., Spapen, H., Wauters, J., Dugernier, T., Jorens, P., Dapper, I., De Backer, D., Taccone, F. S., Rello, J., Ruano, L., Afonso, E., Alvarez-Lerma, F., Gracia-Arnillas, M. P., Fernandez, F., Feijoo, N., Bardolet, N., Rovira, A., Garro, P., Colon, D., Castillo, C., Fernado, J., Lopez, M. J., Fernandez, J. L., Arribas, A. M., Teja, J. L., Ots, E., Carlos Montejo, J., Catalan, M., Prieto, I., Gonzalo, G., Galvan, B., Blasco, M. A., Meyer, E., Del Nogal, F., Vidaur, L., Sebastian, R., Garde, P. M., Martin Velasco, M. D. M., Zaragoza Crespo, R., Esperatti, M., Torres, A., Montravers, P., Baldesi, O., Dupont, H., Mahjoub, Y., Lasocki, S., Constantin, J. M., Payen, J. F., Martin, C., Albanese, J., Malledant, Y., Pottecher, J., Lefrant, J.-Y., Jaber, S., Joannes-Boyau, O., Orban, C., Ostermann, M., McKenzie, C., Berry, W., Smith, J., Lei, K., Rubulotta, F., Gordon, A., Brett, S., Stotz, M., Templeton, M., Rhodes, A., Ebm, C., Moran, C., Kaukonen, K.-M., Pettila, V., Dimopoulos, G., Koulenti, D., Xristodoulou, A., Theodorou, V., Kouliatsis, G., Sertaridou, E., Anthopoulos, G., Choutas, G., Rantis, T., Karatzas, S., Balla, M., Papanikolaou, M., Myrianthefs, P., Gavala, A., Fildisis, G., Koutsoukou, A., Kyriakopoulou, M., Petrochilou, K., Kompoti, M., Michalia, M., Clouva-Molyvdas, F.-M., Gkiokas, G., Nikolakopoulos, F., Psychogiou, V., Malliotakis, P., Akoumianaki, E., Lilitsis, E., Koulouras, V., Nakos, G., Kalogirou, M., Komnos, A., Zafeiridis, T., Chaintoutis, C., Arvaniti, K., Matamis, D., Chaintoutis, C., Kydona, C., Gritsi-Gerogianni, N., Giasnetsova, T., Giannakou, M., Soultati, I., Chytas, I., Antoniadou, E., Antipa, E., Lathyris, D., Koukoubani, T., Paraforou, T., Spiropoulou, K., Bekos, V., Spring, A., Kalatzi, T., Nikolaou, H., Laskou, M., Strouvalis, I., Aloizos, S., Kapogiannis, S., Soldatou, O., Bassetti, M., Adembri, C., Villa, G., Giarratano, A., Maurizio Raineri, S., Cortegiani, A., Montalto, F., Strano, M. T., Ranieri, V. M., Sandroni, C., De Pascale, G., Molin, A., Pelosi, P., Montagnani, L., Urbino, R., Mastromauro, I., De Rosa, F. G., Ranieri, V. M., Cardoso, T., Afonso, S., Goncalves-Pereira, J., Baptista, J. P., Akova, M., & Ozveren, A.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- The University of Queensland (AU)
- Ghent University Hospital (BE)
- Centre Hospitalier Universitaire de Nîmes (FR)
- University General Hospital Attikon (GR)
- Sorbonne Paris Cité (FR)
- St George's, University of London (GB)
- University of Palermo (IT)
- University of Genoa (IT)
- Hacettepe University (TR)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-14
- Volume
- 58
- Issue
- 8
- Pages
- 1072-1083
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101416655
- Cited by
- 1,090
- References
- 31
- Citations by year
- 2026: 75 · 2025: 98 · 2024: 83 · 2023: 125 · 2022: 115 · 2021: 125 · 2020: 86 · 2019: 84 · 2018: 69 · 2017: 71 · 2016: 66 · 2015: 57 · 2014: 34
- FWCI
- 55.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- HAL (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NIHR/CS/009/007)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- beta-lactam antibiotics, antibiotic dosing, critically ill patients, intensive care unit, pharmacokinetics, pharmacodynamics, free drug concentration, time above MIC, patient outcomes
- MeSH terms
- Aged, Anti-Bacterial Agents, Bacterial Infections, Blood Chemical Analysis, Female, Humans, Intensive Care Units, International Cooperation, Male, Microbial Sensitivity Tests, Middle Aged, Prospective Studies, Models, Statistical, Critical Illness, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.